BridgeBio Pharma BBIO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $194.52M+66.8% | $154.18M+2,521% | $120.7M+4,318% | $110.57M+5,000% | $116.63M-44.8% | ||
| $9.94M+277% | $8.11M+289% | $6.56M+997% | $3.65M+511% | $2.64M+341% | ||
| $184.58M+61.9% | $146.07M+3,746% | $114.14M+5,249% | $106.91M+6,710% | $113.99M-45.9% | ||
| 94.9%-2.8pp | 94.7%+30.2pp | 94.6%+16.5pp | 96.7%+24.3pp | 97.7%-2.0pp | ||
| $126.64M+13.6% | $116.42M-10.7% | $112.87M-6.3% | $111.23M-3.0% | $111.43M-21.0% | ||
| $163.9M+54.1% | $158.09M+66.8% | $137.62M+100.0% | $129.15M+117% | $106.37M+61.6% | ||
| $300.47M+36.0% | $293.74M+26.7% | $265.9M+36.7% | $244.84M+37.8% | $221.01M+4.9% | ||
| -$105.96M-1.5% | -$139.56M+38.3% | -$145.2M+24.3% | -$134.28M+23.5% | -$104.37M-30,529% | ||
| -54.5%+35.0pp | -90.5%+3,752pp | -120.3%+6,898pp | -121.4%+7,975pp | -89.5%-89.7pp | ||
| $12.94M-28.6% | $11.64M-45.9% | $11.74M-49.1% | $37.64M+64.1% | $18.12M-22.8% | ||
| -$60.6M+7.1% | -$55.19M— | -$41.28M-250% | -$47.38M-147% | -$65.24M-78.7% | ||
| -$166.56M+1.8% | -$194.64M+27.2% | -$184.94M-12.6% | -$183.76M-143% | -$169.61M-369% | ||
| -85.6%+59.8pp | -126.2%+4,420pp | -153.2%+5,859pp | -166.2%+3,318pp | -145.4%-128pp | ||
| -$0.84+4.5% | -$0.99+30.3% | -$0.95-10.5% | -$0.95-144% | -$0.88-340% | ||
| -$104.77M-1.6% | -$138.13M+38.5% | -$143.8M+24.4% | -$132.96M+23.6% | -$103.09M-5,417% | ||
| -53.9%+34.5pp | -89.6%+3,730pp | -119.1%+6,843pp | -120.3%+7,904pp | -88.4%-89.3pp | ||
| -$105.96M-1.5% | -$139.56M+38.3% | -$145.2M+24.3% | -$134.28M+23.5% | -$104.37M-30,529% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BridgeBio Pharma's revenue?
- BridgeBio Pharma (BBIO) generated $580.0M in revenue over the trailing twelve months, up 355.2% year over year.
- Is BridgeBio Pharma profitable?
- BridgeBio Pharma is not currently profitable: it reported a net loss of $729.9M over the trailing twelve months, a -125.9% net margin.
- What are BridgeBio Pharma's profit margins?
- Gross margin is 95.1% and operating margin is -90.5%, with a -125.9% net margin.
- What is BridgeBio Pharma's earnings per share?
- BridgeBio Pharma's diluted EPS over the trailing twelve months is $-3.73.
- Where does BridgeBio Pharma's income statement data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
